Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

New HIV Drugs - Pifeltro® and Delstrigo®

Monday 15 October 2018

Two new HIV medications have been added to the interaction checker. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and was approved by the FDA in August 2018 for the treatment of HIV-1 in combination with other antiretrovirals in adult patients with no prior antiretroviral treatment experience.

Doravirine is available as a single agent (Pifeltro®) and as a once-daily fixed-dose combination tablet (Delstrigo®) containing doravirine, lamivudine (3TC) and tenofovir-DF (TDF).

SPONSORS
Sponsor logo janssen Sponsor logo gilead Sponsor logo msd Sponsor logo viiv
EDITORIAL SPONSORS
Hiv  glasgow 2018 cmyk logo Eacs logo 2014 Bhiva 2018 Basel text
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016